PharmaLive: EPIX Pharmaceuticals Initiates Phase 2a Clinical Trial in Patients with Mild Alzheimer's Disease

PharmaLive: EPIX Pharmaceuticals Initiates Phase 2a Clinical Trial in Patients with Mild Alzheimer's Disease: "EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX) announced today the initiation of a Phase 2a clinical trial to further evaluate PRX-03140 as monotherapy and in combination with donepezil for the treatment of Alzheimer's disease."